Premium
Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study
Author(s) -
Masuyama Tomoyuki,
Sanui Masamitsu,
Yoshida Naoto,
Iizuka Yusuke,
Ogi Kunio,
Yagihashi Satoko,
Nagatomo Kanae,
Sasabuchi Yusuke,
Lefor Alan K.
Publication year - 2018
Publication title -
psychogeriatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 32
eISSN - 1479-8301
pISSN - 1346-3500
DOI - 10.1111/psyg.12314
Subject(s) - delirium , critically ill , medicine , incidence (geometry) , retrospective cohort study , cohort , intensive care medicine , cohort study , emergency medicine , pediatrics , psychiatry , physics , optics
Background Benzodiazepine use is a risk factor for the development of delirium in adult intensive care unit (ICU) patients. Suvorexant is an alternative to benzodiazepines to induce sleep, but the incidence of delirium in critically ill patients is unknown. We undertook this retrospective study to investigate the incidence of delirium in patients who receive suvorexant in the ICU. Methods This retrospective cohort study was conducted in a closed 12‐bed ICU at a tertiary teaching hospital. Patients admitted to the ICU for 72 h or longer between January and June 2015 were evaluated for delirium using the Confusion Assessment Method for the Intensive Care Unit tool. We evaluated the incidence of delirium in patients who received suvorexant and those who did not. To adjust for confounding factors, multivariable logistic regression analysis was conducted. Results Study subjects included 118 patients, with a median age of 72 years and a median Acute Physiology and Chronic Health Evaluation II score of 18 points. Eighty‐two patients (69.5%) were admitted after cardiovascular surgery. In the suvorexant group, there were fewer post‐cardiovascular surgical patients and more medical patients. The duration of mechanical ventilation during ICU stay was longer in the suvorexant group, and sedatives and sleep inducers other than suvorexant were used more frequently in the suvorexant group. The incidence of delirium was 43.8% in the suvorexant group and 58.8% in the non‐suvorexant group ( P = 0.149). After adjustment for risk factors using multivariable logistic regression analysis, suvorexant was associated with a lower incidence of delirium (odds ratio = 0.23, 95% confidence interval: 0.07–0.73; P = 0.012). Conclusions Suvorexant was associated with decreased odds of transitioning to delirium in critically ill patients. The use of suvorexant may lower the incidence of delirium in ICU patients. Future prospective studies are warranted.